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Abstract
Background: Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are forms of hepatic
autoimmunity, and risk for both diseases has a strong genetic component. This study aimed to define the genetic
architecture of PBC and PSC within the Polish population.
Methods: Subjects were 443 women with PBC, 120 patients with PSC, and 934 healthy controls recruited from
Gastroenterology Departments in various Polish hospitals. Allelotyping employed a pooled-DNA sample-based genome-wide
association study (GWAS) approach, using Illumina Human Omni2.5-Exome BeadChips and the following novel selection
criteria for risk loci: blocks of at least 10 single nucleotide polymorphisms (SNPs) in strong linkage disequilibrium, where the
distance between each adjacent SNP pair in the block was less than 30 kb, and each SNP was associated with disease at a
significance level of P < 0.005. A selected index SNP from each block was validated using TaqMan SNP genotyping assays.
Results: Nineteen and twenty-one SNPs were verified as associated with PBC and PSC, respectively, by individual
genotyping; 19 (10/9, PBC/PSC) SNPs reached a stringent (corrected) significance threshold and a further 21 (9/12, PBC/
PSC) reached a nominal level of significance (P < 0.05 with odds ratio (OR) > 1.2 or < 0.83), providing suggestive evidence
of association. The SNPs mapped to seven (1p31.3, 3q13, 6p21, 7q32.1, 11q23.3, 17q12, 19q13.33) and one (6p21)
chromosome region previously associated with PBC and PSC, respectively. The SNP, rs35730843, mapping to the POLR2G
gene promoter (P = 1.2 × 10-5, OR = 0.39) demonstrated the highest effect size, and was protective for PBC, whereas
for PSC respective SNPs were: rs13191240 in the intron of ADGRB3 gene (P = 0.0095, OR = 0.2) and rs3822659
(P = 0.0051, OR = 0.236) along with rs9686714 (P = 0.00077, OR = 0.2), both located in the WWC1 gene.
(Continued on next page)
* Correspondence: jostrow@warman.com.pl
1Department of Gastroenterology, Hepatology and Oncology, Medical Center
for Postgraduate Education, Warsaw, Poland
2Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Paziewska et al. BMC Medical Genomics  (2017) 10:2 
DOI 10.1186/s12920-016-0239-9
(Continued from previous page)
Conclusions: Our cost-effective GWAS approach followed by individual genotyping confirmed several previously
identified associations and discovered new susceptibility loci associated with PBC and/or PSC in Polish patients.
However, further functional studies are warranted to understand the roles of these newly identified variants in the
development of the two disorders.
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Background
Primary biliary cholangitis (PBC) and primary sclerosing
cholangitis (PSC) are hepatobiliary autoimmune diseases
with strong genetic risk components [1]. PBC is charac-
terized by progressive immune-mediated destruction of
interlobular biliary ductules, and PSC by inflammatory
and fibrotic processes affecting the intrahepatic and ex-
trahepatic biliary tree; both diseases lead to liver cirrho-
sis [1–4]. PBC occurs more frequently in women than
men and primarily in middle-age, with prevalences ran-
ging from 40 to 400 patients per million and incidences
ranging from 0.7 to 49 per million [5–8]. PSC affects 9
to 13 patients per million annually with a male-to-
female ratio of 2:1 [3]. In Western countries, 60–80% of
PSC cases are associated with inflammatory bowel dis-
ease (IBD), while PSC is present in 3–8% of all patients
with ulcerative colitis and 1–3% of patients with Crohn’s
disease [2, 9, 10]. Both PBC and PSC are classic polygenic
disorders, with a genetic load represented by common,
mostly non-protein-coding single nucleotide polymor-
phisms (SNPs), exhibiting similar small effect sizes [1].
Standard genome-wide association studies (GWASs)
use high throughput SNP microarray technologies to
discover SNPs associated with disease. Generally, the
higher the sample size of a GWAS, the higher the num-
ber of the associations that reach the genome-wide sig-
nificance threshold of P < 5 × 10-8 [2]. By contrast,
studies with small sample sizes typically fail to reach
GWAS statistical significance. The largest genetic associ-
ation study for IBDs employed over 75,000 patients and
controls and uncovered 163 IBD susceptibility loci [3].
However, studies of the heritable component of PBC
and PSC by GWAS have been rather limited, primarily
because of the lower prevalence of hepatobiliary auto-
immunity, particularly PSC. While several GWASs have
been performed using well-characterized PBC patient
cohorts from North America, Europe, or Japan, only a few
have included PSC patients mainly from northern Europe
[4]; however, all of these GWASs had relatively small sam-
ple sizes [2]. Despite this, in addition to multiple PSC and
PBC associations within the HLA complex, and with non-
HLA genes mapping to the chromosome 6p21 major
histocompatibility complex (MHC) locus, several associa-
tions have been identified at non-MHC susceptibility loci
with genome-wide significance [6–17].
Many of these are associated with other immune-
mediated diseases, including multiple sclerosis, celiac dis-
ease, and type 1 diabetes (T1D) [17, 18]. However, while
larger GWAS cohorts, combining patients from different
populations, may miss some sub-population-specific risk
variants, smaller GWASs generally suffer from lack of stat-
istical power. As a consequence, in GWASs limited to hun-
dreds of patients, few or no associations at the accepted
genome-wide significance level have been identified.
To identify susceptibility loci for PBC and PSC in the
Polish population, we employed a pooled-DNA GWAS
approach, together with a new method for identifying
SNP associations. Considering the limited sizes of the
cohorts investigated in our GWAS, this approach was ef-
fective in identifying novel PBC and/or PSC susceptibil-
ity loci. Despite the fact that “index SNPs” were selected
at P-values much lower than the standard genome-wide
significance threshold, the majority were validated by in-
dividual TaqMan SNP genotyping assays.
Methods
Studied subjects
Between 2010 and 2014, 443 women with PBC (389
antimitochondrial antibodies positive) and 120 PSC pa-
tients (37 females and 83 males) were recruited at nine
recruitment centers. All enrolled patients and controls
were Polish Caucasians. Diagnosis of PBC was based on
standard clinical, biochemical, serological, and histological
criteria, and PSC was diagnosed according to standard
clinical, biochemical, cholangiographic, and in some pa-
tients - histological criteria according to the European As-
sociation for the Study of Liver (EASL) [19]. Blood
samples were also obtained from 934 healthy individuals
(512 females and 422 males). Sample sizes and age distri-
bution for each group are shown in Table 1.
GWAS allelotyping
A pooled-DNA sample-based GWAS was performed as
described previously [20]. Genomic DNA was extracted
from whole blood treated with EDTA using a QIAamp
DNA Mini Kit. DNA sample concentrations were
measured by a Quant-iTTM PicoGreen dsDNA Kit
(Invitrogen, United Kingdom). DNA integrity was verified
by 1% agarose gel analysis. Those DNA samples that
passed quality control tests were combined according to
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diagnosis at equimolar concentrations to obtain two sets
of DNA pools. The first microarray set consisted of 21, 6
and 30 DNA pools combining 20–24 DNA samples from
PBC patients, PSC patients and healthy controls, respect-
ively, whereas the second set consisted of 11, 3 and 10
DNA pools which were respectively combined from 37
DNA samples of PBC, PSC and controls. Pooled-DNA
samples were adjusted to a final concentration of 50 ng/
ml in Tris-EDTA buffer (pH = 8) and were assayed inde-
pendently on Illumina Human Omni2.5-Exome Bead-
Chips by the external AROS Applied Biotechnology A/S
(Aarhus, Denmark) service.
Individual genotyping
For validating the GWAS findings and the SNP typing
replication study, individual patients and controls were
genotyped with TaqMan SNP Genotyping Assays
(Thermo, USA) using a TaqMan Universal Master Mix
II (Thermo, USA) and a 7900HT Real-Time PCR system
(Thermo, USA).
Statistical analyses – allelotyping GWAS
For each SNP, on each microarray, the relative allele signal
(RAS) was calculated as described previously [20]. RAS
was used as an approximation of the allele ratio. The Stu-
dent’s t-test (Welch variant) was used to compare allele ra-
tios between groups. Due to a lack of the call-rate statistic
for pooled samples, quality was assessed by visual inspec-
tion of first four principal components. A representative
example is shown in Additional file 1: Figure S1. Six/two
control pools were removed as outliers from the first/sec-
ond microarray set, respectively. No probe filtering was
performed. P-values were corrected for multiple hypoth-
esis testing with the Bonferroni algorithm. Manhattan
plotting was performed using the qqman R package [21].
All computations were performed according to R environ-
ment [22]. R: A language and environment for statistical
Table 1 Summary of the main epidemiological variables for the pooled-DNA allelotyping GWASs (A) and validation cohorts (B)
A.
Type Sex Pooled-DNA GWAS
Enrolled (Set I) Enrolled (Set II)
Na Age, range (years) Median age (years) Nb Age, range (years) Median age (years)
PSC Females 40 12–61 31 37 17–52 31
Males 80 9–64 26 74 9–49 26
All 120 9–64 29 111 9–52 28
PBC Females 420 14–85 53 407 29–80 53
Males 0 0 0 0 0 0
420 14–85 53 407 29–80 53
Healthy controls Females 363 3–88 55 222 25–65 43
Males 361 3–69 22 148 28–65 47
All 724 3–88 50 370 25–65 44
B.
Type Sex Individual patient genotyping
Enrolled
N Age, range (years) Median age (years)
PSC Females 41 17–52 31
Males 98 9–64 26
All 139 9–64 29
PBC Females 443 14–85 54
Males 0 0 0
443 14–85 54
Healthy controls Females 512 23–75 48
Males 422 27–78 48
All 934 23–78 47
Panels indicate the number of patients enrolled in the GWAS (Na) after excluding microarrays that did not meet quality control criteria based on principal
component analysis results (Nb) that included validation and replication analyses performed using respective individual patient TaqMan genotyping (N). The range
and median values are the ages of cases and controls in the respective groups in years
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computing. R Foundation for Statistical Computing,
Vienna, Austria. URL http://www.R-project.org/).
Statistical analyses – individual genotyping
Associations were examined using the Fisher-exact test
implemented in R (version 3.1.1). The odds ratios (ORs)
and 95% confidence intervals (CIs) were estimated by nor-
mal approximation using the EpiTools R package [23].
Functional analyses
Symbols of genes to which SNPs mapped (in case of inter-
genic position symbols of both flanking genes) were used
to assign functional overrepresentation using DAVID tool
[24] and Swiss-Prot Protein Information Resource
(SP-PIR) vocabulary.
Results
For association screening, we adopted a cost-effective
pooled-DNA GWAS design [20], which involved two
separate hybridizations. Individual DNA samples from
the same patient cohorts, that passed quality control,
were combined in equimolar amounts, according to pa-
tient diagnosis, to obtain two sets of DNA pools from
the same patients groups; the first set represented 420
PBC patients and 120 PSC patients and the second set,
407 and 111 of these two patient groups, respectively. In
contrast, two different cohorts of 724 and 370 controls
were employed. Selected SNPs, identified by GWAS, were
genotyped using individual DNA samples from the same
cohorts of 443 PBC patients, 120 PSC patients, and 934
control subjects in TaqMan SNP genotyping assays.
The method of selecting loci for validation is crucial for
a successful GWAS. Our relatively small patient cohorts,
particularly the PSC cohort, were statistically unpowered
to detect SNPs associated at the standard threshold for
genome-wide significance (P < 5 × 10-8). Therefore, as-
suming that an “index SNP” at a given locus is usually not
independent of neighboring SNPs, we focused on loci
forming blocks of at least 10 SNPs in strong allele linkage
disequilibrium, defined by the following criteria: the dis-
tance between each pair of adjacent SNPs in the block was
< 30 kb, and each SNP was associated with a disease at a
significance level of P < 0.005. Among blocks meeting
such criteria, we selected “index SNPs” associated with
disease at P < 10-4, which were subsequently subjected to
TaqMan SNP genotyping assays using individual PBC and
PSC patient DNA samples. Although no extensive
optimization of the number of required loci, P-value
threshold, or window size was performed, the algorithm
used was effective.
Primary biliary cholangitis
Two rounds of GWAS led to the selection of 22 SNPs
from 18 blocks of SNPs for validation as associated
with PBC. Of the 22 SNPs, all but one were selected
from the first GWAS, and only one of the seven SNPs
selected from the second GWAS was not also identified
in the first round. Among 22 “index SNPs” subjected to
the genotyping assays, 19 were validated as associated
with PBC, of which 10 reached the significance level
determined by Bonferroni correction for multiple test-
ing (P < 0.0023; 0.05/22), while the remaining nine
demonstrated at least suggestive evidence for associ-
ation, reaching a nominal level of significance (P < 0.05,
with OR > 1.2 or < 0.83) (Additional file 2: Table S1). All
19 had the same direction of effect as observed in GWAS.
In addition, two SNPs (rs3745516 and rs9303277) that
were found to associate with PBC in previous studies
[14, 16] were also confirmed to be associated in our
PBC cohort. For 14 SNPs, the minor allele was associated
with increased disease risk, while for the remaining five
SNPs the minor allele showed a protective effect. The
most significant PBC association (in terms of OR) as de-
termined by genotyping assay was observed with the
POLR2G locus (rs35730843; OR = 0.39; P = 1.2 × 10-5;
SNP located in the gene promoter).
Primary sclerosing cholangitis
Two rounds of GWAS led to selection of 29 SNPs ori-
ginating from 22 blocks of SNPs for validation as asso-
ciated with PSC; 18 and 12 SNPs were selected from
the first and second GWAS rounds, respectively, and
only one SNP was shared between both rounds. From
the 29 SNPs, 21 were defined as associated with PSC
after validation by genotyping assays, of which nine
SNPs reached the level of significance determined by
Bonferroni correction for multiple testing (P < 0.0017;
0.05/29) and 12 reached a nominal level of significance
(P < 0.05 with OR > 1.2 or < 0.83) (Additional file 2:
Table S2). Again, all 21 validated SNPs had the same ef-
fect direction as observed in GWAS. For 10 SNPs, the
minor allele was associated with an increased risk, and
for the other 11 the minor allele showed a protective
effect. The most significant PSC association outside
MHC region, as determined by genotyping assays, were
observed at the WWC1 gene (rs9686714; OR = 0.20;
P = 0.00077; intronic location and rs3822659; OR = 0.24,
P = 0.0051) and at the ADGRB3 intron (rs13191240;
OR = 0.2; P = 0.0095).
In addition, TaqMan SNP genotyping assays were
used to test 18 and 3 SNPs associated with IBD and
celiac disease, respectively, in a previous Polish study
[25]. Of these, eleven and two SNPs were also found to
associate with PBC and PSC, respectively, and another
four SNPs with both PBC and PSC (Table 2). Finally,
to assess which SNPs associated with PBC are shared
loci for susceptibility to PSC and vice versa, all SNPs
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Table 2 Loci validated or replicated by individual patient TaqMan genotyping
Locus SNP Position Location Putative (nearby) gene(s) PBC PSC MA, MAF
P-value OR P-value OR
1p32 rs4927257 56046320 prom. 0.033 0.83 0.026 0.72 A, 0.439
2p25.3 rs1965732 3709108 intron ALLC 0.028 1.24 0.029 1.41 G, 0.266
5q34 rs9686714 167853274 intron WWC1 0.048 0.68 7.7E-4 0.195 C, 0.066
6p21 rs2187668 32605884 intron HLA-DQA1 0.021 0.73 1.53E-7 2.47 T, 0.128
6p21 rs9272346 32604372 prom. HLA-DQA1 0.0067 0.79 0.025 1.37 G, 0.422
6p21 rs7775228 32658079 inter. LOC100294145, C4B_2 7.94E-9 1.84 0.00171 0.46 C, 0.146
6p21 rs3213489 32724305 intron HLA-DQB2 8.37E-9 0.60 0.00155 1.56 T, 0.416
6p21 rs1799908 33144243 intron COL11A2 0.032 1.21 0.0045 0.63 A, 0.405
6p21 rs7454108 32681483 inter. LOC100294145, C4B_2 0.0090 1.43 0.00130 0.326 C, 0.086
9q34.3 rs10119096 139801932 intron TRAF2 0.00087 0.70 0.041 0.70 T, 0.263
10q26.11 rs17098094 120592334 inter. MIR4681, CACUL1 0.0174 0.81 0.032 0.73 G, 0.394
1p31.3 rs10489626 67793171 intron IL12RB2 2.11E-5 1.59 G, 0.179
rs3790567 67822377 intron IL12RB2 8.4E-4 1.37 A, 0.242
1q32.1 rs3024505 206939904 inter. IL24, CTSE 0.047 1.25 A, 0.158
2q31.1 rs2287619 169836730 intron ABCB11 0.0079 1.50 C, 0.076
1q24.3 rs12118836 171256038 inter. MIR3120, MIR1295A 0.0081 1.37 A, 0.145
3q13 rs28413019 109890863 inter. PVRL3-AS1, DPPA2 0.022 1.25 G, 0.237
rs1491590 70657915 inter. MIR1284, MITF 0.0021 1.34 G, 0.251
4p15.1 rs13126571 27725689 inter. TBC1D19 0.031 1.24 A, 0.230
4p14 rs3114381 40533297 intron RBM47 0.0123 1.28 T, 0.232
4q26 rs979961 117850456 inter. TRAM1L1, MIR1973 0.0062 1.39 C, 0.131
6p21 rs9268979 32435044 inter. LOC100294145, C4B_2 6.73E-6 0.68 T, 0.471
6p21 rs3128927 33074288 inter. MIR1275, LOC100294145 2.16E-5 1.50 T, 0.240
6q27 rs4710185 167522386 intron CCR6 0.020 1.23 A, 0.358
6q27 rs9459874 167504127 intron CCR6 0.0040 1.29 T, 0.425
6q27 rs975822 167516458 intron CCR6 0.0042 1.29 T, 0.459
7q32.1 rs10488631 128594183 inter. SMKR1, LOC100130705 0.0023 1.43 C, 0.132
7p14.3 rs965571 33622588 intron BBS9 7.0E-4 1.43 C, 0.207
11q12.3 rs35730843 62527634 prom. POLR2G 1.21E-5 0.393 C, 0.070
11p15.3 rs12786216 11275192 inter. MIR4299, MRVI1-AS1 0.0076 0.77 C, 0.299
11q23.3 rs11217040 118680648 inter. LOC100131626 9.22E-5 0.66 A, 0.246
11q24.3 rs73022813 130704378 inter. SNX19, ADAMTS8 0.043 1.24 A, 0.176
12p13.31 rs7975557 9853697 inter. KLRF2, MIR1244-1 0.042 1.54 T, 0.035
14q21.1 rs10083358 39001998 inter. LOC100288846, MIPOL1 0.0026 1.34 G, 0.252
16p12.3 rs8055224 20285401 inter. ERI2, IQCK 0.0077 0.54 G, 0.050
16q23.3 rs8049648 83217488 intron CDH13 0.00175 1.68 C, 0.061
19q13.33 rs3745516 50926742 intron SPIB 7E-05 1.45 A, 0.254
21q22.11 rs7279062 32074387 inter. KRTAP21-3, KRTAP25-1 0.0110 0.80 T, 0.476
17q12 rs9303277 37976469 intron IKZF3 0.0051 1.27 T, 0.478
3q22.1 rs11917172 132166266 coding DNAJC13 0.0122 0.53 G, 0.138
4p16.1 rs7686718 10171487 inter. CLNK, USP17L10 0.00161 1.63 C, 0.261
6q12 rs13191240 69675459 intron ADGRB3 0.0095 0.2 C, 0.04
5p15.31 rs6869702 6401135 inter. MIR4278, ICE1 0.047 0.74 G, 0.409
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that had been subjected to validation in PBC were also
genotyped in PSC, and those validated in PSC were ge-
notyped in PBC. Altogether, 28 and 18 SNPs were
unique to PBC and PSC, respectively, and eleven SNPs
were shared between PBC and PSC. Of the latter, three
had the same direction of effect in both types of hepa-
tobiliary autoimmunity.
Functional analysis of the merged validated SNP list for
PBC and PSC revealed significant over-representation of
genes associated with immune responses (HLA-DQB1,
HLA-DRB5, HLA-C, HLA-B, HLA-DPB1, HLA-DQA2,
HLA-DQA1, and HLA-DRA; P = 0.023; Additional file 2:
Table S3).
Discussion
GWASs provide information about common variants asso-
ciated with disease susceptibility. Although GWASs allow
the identification of disease risk alleles without prior know-
ledge of their position or biological function, they require
large study cohorts to identify associations at the genome-
wide significance threshold (5 × 10-8). By contrast, smaller
GWASs using the same threshold may generate false-
negative results. For association screening, we performed
pooled-DNA GWASs and applied novel selection criteria
that took into account strong allele linkage disequilibrium.
We selected SNP blocks, defined by a distance of less than
30 kb between each pair of at least 10 SNPs associated with
disease at P < 5 × 10-3, with an “index SNP” in the block
for which the association was significant at P ≤ 10-4. All of
the associations identified using this approach would
have been missed using the standard genome-wide sig-
nificance threshold. Of 22 and 29 associations with
PBC and PCS, respectively, selected for validation, 19
and 21 SNPs were verified using TaqMan SNP
genotyping assays of individual patient and control
samples. In total, 19 SNPs reached the stringent (cor-
rected) significance threshold, while the other 21
reached a nominal level of significance (P < 0.05 with
OR > 1.2 or < 0.83), demonstrating at least suggestive
evidence for association (Table 2). However, the expected
number of false-positive results for 50 independent tests,
with a significance threshold of 0.05, is < 3, while appro-
priate correction for multiple comparisons would reduce
this to < 1. In our validation studies, correction for mul-
tiple testing reduced the number of associations at the
nominal level of significance from 40 to 19, thus likely
generating a large number of false-negative results and
only slightly reducing the expected number of false-
positive results.
This study identified 57 SNPs associated with either
PBC or PSC or both disorders, which represent 38 gen-
etic regions (Table 2). As expected, there were higher
numbers of associations with HLA and non-HLA loci
mapping to the MHC region (chromosome 6p21). Of 13
SNPs from this region, two, five, and six SNPs were as-
sociated with PBC, PSC, and both disorders, respect-
ively. Of the SNPs shared between PBC and PSC, only
two exhibited the same direction of effect.
As both PBC and PSC are hepatobiliary autoimmune
diseases with low prevalence, the largest GWASs of
these diseases have recruited individuals from different
populations, which has certainly introduced a level of
heterogeneity into the results, arising from the different
genetic backgrounds of the geographically distinct popu-
lations. Consequently, these large cohort studies may
have missed some subtle, sub-population-specific risk
variants that may account for missing heritability. Con-
versely, studies with smaller sample sizes typically reveal
Table 2 Loci validated or replicated by individual patient TaqMan genotyping (Continued)
5q22.2 rs1554624 111655382 intron EPB41L4A 0.0126 0.55 G, 0.154
5q34 rs3822659 167858372 coding WWC1 0.0051 0.24 TG, 0.053
6p21 rs3130484 31715882 intron MSH5-SAPCD1 5.12E-11 3.23 C, 0.101
6p21 rs1264377 30764907 inter. PSORS1C3, MIR877 8.02E-8 2.39 A, 0.159
6p21 rs2524163 31259579 intron HLA-B 5.94E-7 2.02 C, 0.429
6p21 rs3130626 31598489 intron PRRC2A 1.5E-6 2.10 G, 0.207
6p21 rs419788 31928799 intron SKIV2L 1.21E-6 2.03 T, 0.250
6p22.1 rs3815081 30114074 intron TRIM40 0.0141 0.59 G, 0.169
rs1936365 28268452 intron PGBD1 0.0034 1.72 C, 0.128
11q24.3 rs34708188 128223560 inter. SENCR 0.0057 2.27 T, 0.038
7q35 rs954072 144757945 inter. CTAGE4 0.0069 0.66 C, 0.406
8q21.13 rs1380634 80237893 inter. MIR5708, LOC101241902 0.001011 1.70 G, 0.241
15q21.3 rs11853454 54169638 inter. UNC13C, WDR72 0.040 1.39 A, 0.218
17p13.2 rs238224 4863410 intron SPAG7 0.0174 0.57 A, 0.146
Map loci refer to the GRCh37 assembly. SNPs chosen on the basis of Celiac disease and IBD association are bolded. Odds ratios (ORs) are for minor alleles. SNP
single nucleotide polymorphism, MA minor allele, MAF minor allele frequency; inter., intergenic (location); prom., promoter
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a smaller fraction of the heritability of a complex disease,
as they fail to detect associations because any found do
not reach statistical significance thresholds [26]. The rela-
tive homogeneity of the Polish population may explain, at
least in part, why our investigation identified so many
SNPs significantly associated with PBC and/or PSC.
A GWAS including 536 North American PBC patients
uncovered disease associations for several gene variants in
the HLA class II region and coding variants in the
interleukin-12a (IL12A) and IL12 receptor b2 (IL12RB2)
genes [11]. Further GWASs have replicated these findings
in a European population, and identified additional risk
genes overlapping with other autoimmune diseases [17,
18]. In six GWASs, 27 non-HLA risk loci associated with
PBC were identified [4]. Most have also been implicated in
other autoimmune diseases, highlighting different immu-
noregulatory pathways. Our findings indicated the possible
involvement of six previously described regions (1p31.3,
rs3790567 [11]; 3q13 [13, 16]; 7q32.1, rs10488631 [12, 14];
11q23.3 [13, 16]; 17q12, rs9303277 [18]; and 19q13.33,
rs3745516 [14]) and the HLA-containing 6p21 locus in the
development of PBC in Polish patients (Table 2).
Genomic studies of PSC have uncovered 18 associated
genetic regions: 1p36 (TNFRSF14, MMEL1); 2q13
(BCL2L1); 2q33 (CD28); 2q35 (GPBAR1); 2q37.3 (GPR35);
3p21 (USP4, MST1); 4q27 (IL2, IL21); 6q15 (BACH2);
6p21 (HLA region); 10p15 (IL2RA); 11q23 (SIK2); 12q13
(HDAC7); 12q24 (SH2B3, ATXN2); 13q31 (GPC5/6);
18q21.1 (TCF4); 18q22 (CD226); 19q13 (PRKD2, STRN4);
and 21q22 (PSMG1) [5, 6, 8, 27, 28]. Of these, only the
MHC region was replicated in our PSC patients (Table 2).
The MHC region, which contains more than 224 genes
and is highly polymorphic, is known to be associated with
more than 100 different autoimmune and infectious
diseases [29–31]. In European-based GWASs, the most
pronounced MHC associations with PSC were with
class I (HLA-B and -C) rather than class II (HLA-DRB1
and -DQB1) loci [27]. A meta-analysis of three inde-
pendent PBC cohorts identified HLA class II alleles
(HLA-DRB1, HLA-DQA1, and HLA-DQB1) achieving
genome-wide significance levels, with similar allele fre-
quencies in Canadian, US, and Italian PBC cohorts
[15]. Outside of the MHC region, our investigation
confirmed six and zero genetic regions uncovered by
previous GWASs as associated with PBC and PSC, re-
spectively [27]. Of 30 chromosomal regions representing
novel susceptibility loci, 13, 9, and 8 were associated with
PBC, PSC, and both disorders, respectively. Of these, 17
SNPs have a shared genetic association with IBD, three
with rheumatoid arthritis, two with lupus erythematosus,
and single SNPs with psoriasis, lateral sclerosis, T1D, and
intrahepatic cholestasis of pregnancy.
While well-designed GWASs should be conducted
with groups of at least 1,000 patients and 1,000 controls,
the appropriate level of statistical power to test for gen-
etic associations (at P < 5 × 10-8) often relates to higher
effect sizes [32]. However, since loci with a high effect
size have generally been efficiently removed from the
human population by natural selection, the identification
of a common polymorphic susceptibility locus strongly
associated with disease, with an OR > 2 or < 0.5, is un-
likely [33]. Instead, a large number of previously identi-
fied loci associated with different disorders exhibit
relatively small effect sizes, with ORs < 1.3. The present
study uncovered only one SNP (rs35730843, POLR2G,
P = 1.2 × 10-5, OR = 0.393) strongly associated with
PBC and 11 SNPs strongly associated with PSC
(rs3822659, coding in WWC1, P = 0.0051, OR = 0.236;
rs9686714, intron of WWC1, P = 0.00077, OR = 0.195;
rs13191240, intron of ADGRB3, P = 0.0095, OR = 0.2;
rs7454108, intergenic between LOC100294145 and
C4B_2, P = 0.0013, OR = 0.326; rs2524163, intron of
HLA-B, P = 5.9 × 10-7, OD = 2.02; rs2187668, intron of
HLA-DQA1, P = 1.5 × 10-7, OR = 2.47; rs3130484, intron
of MSH5-SAPCD1, P = 5.1 × 10-11, OR = 3.23; rs1264377,
intergenic between PSORS1C3 − MIR877, P = 8 × 10-8,
OR = 2.39; rs3130626, intron of PRRC2A, P = 1.5 × 10-6,
OR = 2.10; rs419788, intron of SKIV2L, P = 1.2 × 10-6,
OR = 2.03; and rs34708188, intergenic close to SENCR,
P = 0.0056, OR = 2.27). Of these, nine SNPs map to the
MHC region (6p21), while POLR2G, WWC1, and
ADGRB3 are located in other genomic regions.
Our results indicated that a rare variant in the
POLR2G gene promoter is associated with decreased risk
of PBC, with a high effect size in the Polish population.
POLR2G encodes one of the subunits in the polymerase
2 RNA complex, which is responsible for transcribing
protein coding genes, miRNAs, and some classes of
non-coding RNAs [34] and maps to the 11q12.3 locus,
within which variants associated with chronic obstruct-
ive pulmonary disease [35] and asthma [36] have been
identified. We also identified a decreased risk for PCS
(OR < 0.25) conferred by a single rare variant in the
ADGRB3 gene and two rare variants (rs3822659 and
rs9686714) in the WWC1 gene. ADGRB3 encodes trans-
membrane adhesion G protein-coupled receptor B3
(BAI3), which is broadly expressed in the brain and in-
volved in the regulation of excitatory synapse connectivity
[37]. Furthermore, BAI3 can promote myoblast fusion in
vertebrates [38]. A previous GWAS identified SNPs at the
ADGRB3 locus as associated with early-onset venous
thromboembolism [39]. WWC1 encodes the KIBRA pro-
tein that plays versatile roles including in the regulation of
cellular signaling, cell polarity, vesicular trafficking, and
cell migration and division [40]. Specifically, KIBRA is a
regulator of the Hippo signaling pathway, which controls
tissue growth and tumorigenesis by inhibiting cell prolifer-
ation and promoting apoptosis [41]. Notably, WWC1
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hypermethylation occurs in 70% of B-cell acute lympho-
cytic leukemias [42] and its epigenetic silencing is also as-
sociated with unfavorable prognostic parameters in
chronic lymphocytic leukemia [43]. Interestingly, the trig-
gering of IL-6 trans-signaling, a process of aggregation of
extracellular soluble IL-6 receptor and IL-6 associated
with rheumatoid arthritis [44] and IBD [45], significantly
increased WWC1 expression in human airway smooth
muscle cells [46], suggesting a link between its expression
and inflammatory diseases. Importantly, rs3822659 is a
missense variant (Ser735Ala) that alters the interaction of
KIBRA with phosphatidylinositol 3-phosphate [47]. Other
GWASs have implicated SNPs in WWC1 as associated
with memory performance and cognition [48], as well as
Alzheimer’s disease [49].
Conclusions
To the best of our knowledge, we have performed the first
GWAS of PBC and PSC patients from the Polish popula-
tion. Our cost-effective GWAS approach, followed by indi-
vidual genotyping, allowed us to confirm several previously
described associations and discover new susceptibility loci
associated with both diseases. Although GWASs allow
scanning of the entire genome to identify disease risk alleles
without prior knowledge of their position or biological
function, the use of statistical, rather than biological, criteria
for selection of association findings greatly limits our un-
derstanding of the role of newly identified variants related
to disease development. More importantly, the contribution
of the genetic landscape in the context of environmental
factors, and interactions between these two influences in
conferring susceptibility to disease, has yet to be elucidated.
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